Relying on Renagel
In the second of a two-part series focused on Genzyme's European operations, In Vivo Europe Rx looks at how Genzyme is addressing the challenges facing Renagel's uptake in Europe-cost-conscious reimbursement authorities, cheaper competitors and conservative physicians-in order to secure its most important mid-term growth source.
You may also be interested in...
Actelion didn't exactly hit the jackpot when OGS signed the Swiss company up to market its embattled Zavesca in Europe. But the move will cost Actelion little, and highlights that company's emerging status as a product-focused and independent biotech company, and a valuable marketing partner for niche drugs.
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.
Oncology and rare diseases dominate the industry pipeline, fuelled by science, regulatory tailwinds and high prices. But as the world grapples with coronavirus, and with heart disease still the top killer, can our systems fund treatments for more prevalent conditions?